Тромбофилические риски современной гормональной контрацепции


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

В статье изложены данные литературы о влиянии современных гормональных контрацептивов на риск тромбофилических осложнений, приведена сравнительная характеристика различных синтетических гестагенов и эстрогенов в отношении развития артериальных и венозных тромбозов.

Полный текст

Доступ закрыт

Об авторах

О. А Пустотина

РУДН

Email: pustotina@gmail.com
д.м.н., проф. кафедры акушерства, гинекологии и репродуктивной медицины ФПК МР

Список литературы

  1. US Selected Practice Recommendations for Contraceptive Use, 2013. http://www.cdc.gov/mmwr/pdf/rr/rr62e0614.pdf.
  2. WHO. Medical eligibility criteria for contraceptive use. Fouth edition, 2009. 125 p.
  3. Alkema L., Kantorova V., Menozzi C., Biddlecom A. National, regional, and global rates and trendsin contraceptive prevalence and unmet need for family planing between 1990 and 2015: a systematic and comprehensive analysis. Lanset. 2013; 381: 1642-51.
  4. Lopez L.M., Steiner M., Grimes D.A., et al. Strategies for communicating contraceptive effectiveness. Cochrane Database Syst. Rev. 2013; 4: CD006964.
  5. Lidegaard O. Hormonal contraception and venous thromboembolic risk in mid life women. Editorial. Maturitas. 2013; 74: 1-8.
  6. van Hylckama Vlieg A., Helmerhorst F.M., Vandenbroucke J.P., et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-controlstudy. BMJ. 2009; 339: b2921.
  7. FDA. Office of surveillance and epidemiology. Combined hormonal contraceptives (CHCs) and the risk of cardiovascular disease endpoints. 2011. www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf.
  8. WHO. Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Acute myocardial in farction and combined oral contraceptives: results of aninternational multicentrecase-control study. Lancet. 1997; 349: 1202-09.
  9. Lidegaard O., Lokkegaard E., Jensen A., et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N. Engl. J. Med. 2012; 366: 2257-66.
  10. Chan W.S., Ray J., Wai E.K., et al. Risk of stroke in women exposed to low-dose oral contraceptives: a critical evaluation of the evidence. Arch Intern. Med. 2004; 164: 741-47.
  11. Knopp R.H., LaRosa J.C., Burkman Jr R.T. Contraception and dyslipidemia. Am. J. Obstet. Gynecol. 1993: 168; 1994-2005.
  12. Lubianca J.N., Faccin C.S., Fuchs F.D. Oral contraceptives% a risk factor for uncontrolled blood pressure among hypertensive women. Contraception. 2003; 67: 19-24.
  13. Tepper N.K., Curtis K.M., Steenland M.W., Marchbanks P.A. Blood pressure measurement prior to initiating hormonal contraception: a systematic review. Contraception. 2013; 87: 631-40.
  14. Sherif K. Benefits and risks of oral contraceptives. Am. J. Obstet. Gynecol. 1999; 180(6Pt2): 343-48.
  15. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of aninternational multicentrecase-controlstudy. Contraception. 1998; 57: 315-24.
  16. Sidneya S., Cheethamb T., Frederick A., et al. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. Contraception. 2012; 87: 93-100.
  17. Raps M., Helmerhost F., Fleisher K., et al. Sexhormone-bindingglobulinas a marker for the thrombotic risk of hormonal contraceptives. J. Thromb. Haemost. 2012; 10(6): 992-97.
  18. Lidegaard O., Nielsen L.H., Skovlund C.W., Lokkegaard E. Venous thrombosis in users of nonoral hormonal contraception: follow-upstudy, Denmark, 2001-10, BMJ. 2012; 344: e2990.
  19. Parkin L., Sharples K., Hernandez R., Jick S. 2011. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ. 2011; 342: d2139.
  20. Lidegaard O., Nielsen L.H., Skovlund C.W., et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogendoses: Danishcohortstudy, 2001-9. BMJ. 2011; 343: d6423.
  21. Dinger J., Heinemann L., Khl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contrac. 2007; 75(5): 344-54.
  22. Heit J., Kobbervig C., James A., Petterson T., Bailey K., Melton L. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: A 30-year population-based study. Ann intern Med. 2005; 143(10): 697-706.
  23. Manzoli L., Vito C., Marzuillo C., et al. Oral contraceptives and Venous Thromboembolism a systematic review and meta-analysis. Drug Saf. 2012; 35(3): 191-205.
  24. Dinger J., Assmann A., Möhner S., Minh T.D. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. J. Fam. Plann. Reprod. Health Care. 2010; 36: 123-29.
  25. Kemmeren J.M., Algra A., Meijers J.C., et al. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial. Blood. 2004; 103: 927-33.
  26. Руководство по контрацепции / Под ред. В.Н. Прилепской. Изд. 2-е, перераб. и доп. М., 2010. 444 с.
  27. Royal College of General Practitioners: Oral contraceptives, venous thrombosis and varicose veins. J. R. Coll. Gen. Pract. 1978; 28: 393-99.
  28. Westhoff C., Kaunitz A.M., Korver T., et al. Efficacy, safety, and tolerability of a monophasic oral contraceptive containing nomegestrolacetate and 17β-estradiol: a randomized controlled trial. Obstet. Gynecol. 2012; 119: 989-99.
  29. Agren U.M., Anttila M., Maenpaa-Liukko K., et al. Effects of a monophasic combined oral contraceptive containing nomegestrolacetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism. Eur. J. Contracept. Reprod. Health. Care 2011; 16: 444-57.
  30. Jensen J.T. Evaluationof a new estradiol oral contraceptive: estradiol valerate and dieogest. Expert. Opin. Pharmacother. 2010; 11: 1147-57.
  31. Grow D.R. Metabolism of endogenous and exogenous reproductive hormones. Obstet. Gynecol. Clin. North Am. 2002; 29: 425-36.
  32. Gerstman B.B., Piper J.M., Tomita D.K., et al. Oral contraceptive estrogen dose and risk of deep venous thromboembolic disease. Am. J. Epidem. 1991; 133: 32-37.
  33. Vlieg A.V.H., Helmerhorst F.M., Vandenbroucke J.P., et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009; 339: b2921.
  34. Sandset P.M., Hoibraaten E., Eilertsen A.L., Dahm A. Mechanism soft hrombosis related to hormone therapy. Thromb. Res. 2009; 123(2): 70-3.
  35. Odlind V., Milsom I., Persson I.,Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet. Gynecol. Scand. 2002; 81: 482-90.
  36. Fleischer K., vanVliet H.A., Rosendaal F.R., et al. Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-overstudy. Thromb. Res. 2009; 123: 429-35.
  37. Johnson J.V., Lowell J., Badger G.J., et al. Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial. Obstet. Gynecol. 2008; 111: 278-84.
  38. Lidegaard O., Lokkegaard E., Svendsen A.L., Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-upstudy. BMJ. 2009; 339: b2890.
  39. Grimes D.A., Lopez L.M., O'Brien P.A., Raymond E.G. Progestin-only pills for contraception. Cochrane Database Syst. Rev. 2010; (1): CD007541.
  40. Baillargeon J.P., McClish D.K., Essah P.A., Nestler J.E. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin. Endocrinol. Metab. 2005; 90: 3863-70.
  41. van Hylckama Vlieg A., Helmerhorst F.M., Rosendaal F.R. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel in trauterine device. Arterioscler. Thromb. Vasc. Biol. 2010; 30: 2297-3000.
  42. Alexander N.J., Baker E., Kaptein M., et al. Why consider vaginal drug administration? Fertility Sterility. 2004; 82(1): 1-12.
  43. Brito M.B., Rui A., Ferriani J.C.M. Effects of the etonogestrel-releasing contraceptive implant inserted immediately postpartum on maternal hemostasis: A randomized controlled trial. Thrombosis Res. 2012; 130: 355-60.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2014

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах